Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with Sciometrix Inc. ("Sciometrix"), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummated, result in Tevogen holding a majority voting interest in Sciometrix.The potential transaction is being explored to augment Tevogen's existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise. Tevogen is evaluating the integration of Sciometrix's digital care management capabilities, including its Clinicus platform, and remote patient monitoring technologies, with the Tevogen.AI initiative.Tevogen believes the acquisition may:Accelerate Tevogen's commercialization readiness by integrating clinical development with real-world patient engagement and outcomes tracking.Enhance Tevogen.AI and Tevogen's data capabilities through Clinicus' predictive analytics and care optimization platform.Support value-based models for advanced immunotherapies by aligning treatment delivery with longitudinal patient monitoring and payer reporting requirements.Create a differentiated biotech-plus-services model designed to reduce friction between innovation, reimbursement, and patient access.Optimize clinical trials and related operational efficiency.Abhishek Sharma, Founder and Chief Executive Officer of Sciometrix, stated, "Today marks a major milestone for Sciometrix and Clinicus and the many patients who rely on our high-quality, cost-effective digital healthcare platform to deliver healthcare in their own environment. Our comprehensive care management service has achieved major milestones in the past year, resulting in Sciometrix becoming a top 25 digital healthcare companies in the USA. With the addition of Tevogen.AI's capabilities, we aim to jump into the top 10 next year."Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, "Our objective is to build a fully integrated healthcare ecosystem designed to support patients across all socioeconomic backgrounds. This proposed transaction, if completed, could further advance that vision."The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive ...Full story available on Benzinga.com
2026-02-26 14:20:00